Antony S. Dimitrov

Dr. Antony S. Dimitrov

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
TGThomas W. Geisbert
Thomas W. Geisbert
KBKathryn Bobb
Kathryn Bobb
VBViktoriya Borisevich
Viktoriya Borisevich
JGJoan B. Geisbert
Joan B. Geisbert
KAKrystle N. Agans
Krystle N. Agans
ADAntony S. Dimitrov
Antony S. Dimitrov
Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting.

29 April 2021 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
HDHA DANG
HA DANG
RCRobert W. Cross
Robert W. Cross
VBViktoriya Borisevich
Viktoriya Borisevich
ZBZachary A. Bornholdt
Zachary A. Bornholdt
BWBrandyn R. West
Brandyn R. West
DVDavid Veesler
David Veesler

3 April 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
LZLarry Zeitlin
Larry Zeitlin
RCRobert W. Cross
Robert W. Cross
CWCourtney Woolsey
Courtney Woolsey
BWBrandyn R. West
Brandyn R. West
VBViktoriya Borisevich
Viktoriya Borisevich
Christopher BroderChristopher Broder
Christopher Broder
No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra virus (HeV) G glycoprotein, m102.4, has been tested in a phase 1 trial and has been provided under compassionate use for both HeV and NiV exposures. NiV is a highly pathogenic zoonotic paramyxovirus causing regular outbreaks in humans and animals in South and Southeast Asia. The mortality rate of NiV infection in humans ranges from 40% to more than 90%, making it a substantial public health concern. The NiV G glycoprotein mediates host cell attachment, and the F glycoprotein facilitates membrane fusion and infection. We hypothesized that a mAb against the prefusion conformation of the F glycoprotein may confer better protection than m102.4. To test this, two potent neutralizing mAbs against NiV F protein, hu1F5 and hu12B2, were compared in a hamster model. Hu1F5 provided superior protection to hu12B2 and was selected for comparison with m102.4 for the ability to protect African green monkeys (AGMs) from a stringent NiV challenge. AGMs were exposed intranasally to the Bangladesh strain of NiV and treated 5 days after exposure with either mAb (25 milligrams per kilogram). Whereas only one of six AGMs treated with m102.4 survived until the study end point, all six AGMs treated with hu1F5 were protected. Furthermore, a reduced 10 milligrams per kilogram dose of hu1F5 also provided complete protection against NiV challenge, supporting the upcoming clinical advancement of this mAb for postexposure prophylaxis and therapy.

19 December 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
VLVictor Leyva-Grado
Victor Leyva-Grado
DPD. Promeneur
D. Promeneur
KAK. N. Agans
K. N. Agans
GLG. G. Lazaro
G. G. Lazaro
VBV. Borisevich
V. Borisevich
TGT. W. Geisbert
T. W. Geisbert
The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.

28 April 2023 in Viruses
Verified
Journal Article
Open access
PDF file
MAMoushimi Amaya
Moushimi Amaya
RYRandy Yin
Randy Yin
LYLianying Yan
Lianying Yan
VBViktoriya Borisevich
Viktoriya Borisevich
BABishwo Adhikari
Bishwo Adhikari
Christopher BroderChristopher Broder
Christopher Broder
The henipaviruses, Nipah virus (NiV), and Hendra virus (HeV) can cause fatal diseases in humans and animals, whereas Cedar virus is a nonpathogenic henipavirus. Here, using a recombinant Cedar virus (rCedV) reverse genetics platform, the fusion (F) and attachment (G) glycoprotein genes of rCedV were replaced with those of NiV-Bangladesh (NiV-B) or HeV, generating replication-competent chimeric viruses (rCedV-NiV-B and rCedV-HeV), both with and without green fluorescent protein (GFP) or luciferase protein genes. The rCedV chimeras induced a Type I interferon response and utilized only ephrin-B2 and ephrin-B3 as entry receptors compared to rCedV. The neutralizing potencies of well-characterized cross-reactive NiV/HeV F and G specific monoclonal antibodies against rCedV-NiV-B-GFP and rCedV-HeV-GFP highly correlated with measurements obtained using authentic NiV-B and HeV when tested in parallel by plaque reduction neutralization tests (PRNT). A rapid, high-throughput, and quantitative fluorescence reduction neutralization test (FRNT) using the GFP-encoding chimeras was established, and monoclonal antibody neutralization data derived by FRNT highly correlated with data derived by PRNT. The FRNT assay could also measure serum neutralization titers from henipavirus G glycoprotein immunized animals. These rCedV chimeras are an authentic henipavirus-based surrogate neutralization assay that is rapid, cost-effective, and can be utilized outside high containment.

1 September 2021 in Vaccine
Verified
Journal Article
Open access
JEJohn H. Eldridge
John H. Eldridge
MEMichael A. Egan
Michael A. Egan
DMDemetrius Matassov
Demetrius Matassov
SHStefan Hamm
Stefan Hamm
LHLuz Hermida
Luz Hermida
RCRobert T. Chen
Robert T. Chen
Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum phosphate. This vaccine is currently under clinical evaluation in a Phase 1 study. The Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template may also help contribute to improved public acceptance and communication of licensed protein vaccines.